Anti Thymocyte Globulin-Based Treatment for Acquired Bone Marrow Failure in Adults
Idiopathic acquired aplastic anemia can be successfully treated with Anti Thymocyte Globulin (ATG)-based immune suppressive therapy and is therefore considered a T cell-mediated auto immune disease. Based on this finding, several other forms of idiopathic acquired bone marrow failure are treated wit...
Guardado en:
Autores principales: | , , |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
MDPI AG
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/dfced9c7352f494ba3359605390d7ce9 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
id |
oai:doaj.org-article:dfced9c7352f494ba3359605390d7ce9 |
---|---|
record_format |
dspace |
spelling |
oai:doaj.org-article:dfced9c7352f494ba3359605390d7ce92021-11-25T17:08:47ZAnti Thymocyte Globulin-Based Treatment for Acquired Bone Marrow Failure in Adults10.3390/cells101129052073-4409https://doaj.org/article/dfced9c7352f494ba3359605390d7ce92021-10-01T00:00:00Zhttps://www.mdpi.com/2073-4409/10/11/2905https://doaj.org/toc/2073-4409Idiopathic acquired aplastic anemia can be successfully treated with Anti Thymocyte Globulin (ATG)-based immune suppressive therapy and is therefore considered a T cell-mediated auto immune disease. Based on this finding, several other forms of idiopathic acquired bone marrow failure are treated with ATG as well. For this review, we extensively searched the present literature for evidence that ATG can lead to enduring remissions in different forms of acquired multi- or single-lineage bone marrow failure. We conclude that ATG-based therapy can lead to an enduring hematopoietic response and increased overall survival (OS) in patients with acquired aplastic aplasia. In patients with hypocellular myelodysplastic syndrome, ATG can lead to a hematological improvement without changing the OS. ATG seems less effective in acquired single-lineage failure diseases like Pure Red Cell Aplasia, Amegakaryocytic Thrombocytopenia and Pure White Cell Aplasia, suggesting a different pathogenesis in these bone marrow failure states compared to aplastic anemia. T cell depletion is hypothesized to play an important role in the beneficial effect of ATG but, as ATG is a mixture of polyclonal antibodies binding to different antigens, other anti-inflammatory or immunomodulatory effects could play a role as well.Jennifer M.-L. TjonSaskia M. C. LangemeijerConstantijn J. M. HalkesMDPI AGarticleacquired bone marrow failureaplastic anemiapure red cell aplasiaamegakaryocytic thrombocytopeniapure white cell aplasiamyelodysplastic syndromeBiology (General)QH301-705.5ENCells, Vol 10, Iss 2905, p 2905 (2021) |
institution |
DOAJ |
collection |
DOAJ |
language |
EN |
topic |
acquired bone marrow failure aplastic anemia pure red cell aplasia amegakaryocytic thrombocytopenia pure white cell aplasia myelodysplastic syndrome Biology (General) QH301-705.5 |
spellingShingle |
acquired bone marrow failure aplastic anemia pure red cell aplasia amegakaryocytic thrombocytopenia pure white cell aplasia myelodysplastic syndrome Biology (General) QH301-705.5 Jennifer M.-L. Tjon Saskia M. C. Langemeijer Constantijn J. M. Halkes Anti Thymocyte Globulin-Based Treatment for Acquired Bone Marrow Failure in Adults |
description |
Idiopathic acquired aplastic anemia can be successfully treated with Anti Thymocyte Globulin (ATG)-based immune suppressive therapy and is therefore considered a T cell-mediated auto immune disease. Based on this finding, several other forms of idiopathic acquired bone marrow failure are treated with ATG as well. For this review, we extensively searched the present literature for evidence that ATG can lead to enduring remissions in different forms of acquired multi- or single-lineage bone marrow failure. We conclude that ATG-based therapy can lead to an enduring hematopoietic response and increased overall survival (OS) in patients with acquired aplastic aplasia. In patients with hypocellular myelodysplastic syndrome, ATG can lead to a hematological improvement without changing the OS. ATG seems less effective in acquired single-lineage failure diseases like Pure Red Cell Aplasia, Amegakaryocytic Thrombocytopenia and Pure White Cell Aplasia, suggesting a different pathogenesis in these bone marrow failure states compared to aplastic anemia. T cell depletion is hypothesized to play an important role in the beneficial effect of ATG but, as ATG is a mixture of polyclonal antibodies binding to different antigens, other anti-inflammatory or immunomodulatory effects could play a role as well. |
format |
article |
author |
Jennifer M.-L. Tjon Saskia M. C. Langemeijer Constantijn J. M. Halkes |
author_facet |
Jennifer M.-L. Tjon Saskia M. C. Langemeijer Constantijn J. M. Halkes |
author_sort |
Jennifer M.-L. Tjon |
title |
Anti Thymocyte Globulin-Based Treatment for Acquired Bone Marrow Failure in Adults |
title_short |
Anti Thymocyte Globulin-Based Treatment for Acquired Bone Marrow Failure in Adults |
title_full |
Anti Thymocyte Globulin-Based Treatment for Acquired Bone Marrow Failure in Adults |
title_fullStr |
Anti Thymocyte Globulin-Based Treatment for Acquired Bone Marrow Failure in Adults |
title_full_unstemmed |
Anti Thymocyte Globulin-Based Treatment for Acquired Bone Marrow Failure in Adults |
title_sort |
anti thymocyte globulin-based treatment for acquired bone marrow failure in adults |
publisher |
MDPI AG |
publishDate |
2021 |
url |
https://doaj.org/article/dfced9c7352f494ba3359605390d7ce9 |
work_keys_str_mv |
AT jennifermltjon antithymocyteglobulinbasedtreatmentforacquiredbonemarrowfailureinadults AT saskiamclangemeijer antithymocyteglobulinbasedtreatmentforacquiredbonemarrowfailureinadults AT constantijnjmhalkes antithymocyteglobulinbasedtreatmentforacquiredbonemarrowfailureinadults |
_version_ |
1718412684296192000 |